https://www.live-feeds.com/feed/insilico-s-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-tooContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/insilico-s-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-toohttps://www.live-feeds.com/feed/insilico-s-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-too#u63906Thu, 10 Sep 2026 11:46:04 +0000Insilico Medicine has dosed the first patient with rentosertib, also known as ISM001-055 or INS018_055, in the GENESIS-IPF-3 Phase III clinical trial. The generative AI-discovered drug targets idiopathic pulmonary fibrosis, a severe lung disease. Clinical testing will evaluate lung-function decline over 52 weeks across 47 Chinese sites. Earlier findings indicate the experimental treatment made patients appear biologically younger by an average of three to four years, presenting a potential dual application in treating organ scarring and slowing aging markers.Why it mattersRentosertib represent https://www.live-feeds.com/feed/insilico-s-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-toohttps://www.live-feeds.com/feed/insilico-s-co-ceo-has-big-hopes-that-fibrosis-drug-can-reverse-aging-too#u61889Tue, 08 Sep 2026 21:40:17 +0000Insilico Medicine reports that an AI-generated drug candidate intended for fibrosis can reverse biological age markers and slow aging. Early data from a clinical study indicates the drug candidate impacts biological age, while a phase 2a trial has integrated proteomic aging clocks to allow for simultaneous geroprotective assessment. The company's Co-CEO believes the fibrosis treatment possesses the potential to reverse aging processes. These findings suggest a dual application for the AI-discovered compound in treating specific organ scarring and extending healthy lifespan.Why it mattersA